NASDAQ:XDNA Kelly CRISPR & Gene Editing Technology ETF (XDNA) Price, Holdings, & News $7.38 0.00 (0.00%) As of 09/23/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartOptions Chain About Kelly CRISPR & Gene Editing Technology ETF (NASDAQ:XDNA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get XDNA alerts:Sign Up Key Stats Today's Range$7.38▼$7.3850-Day Range$7.38▼$7.3852-Week Range$5.87▼$11.83VolumeN/AAverage Volume3,034 shsMarket Capitalization$2.21 millionAssets Under Management$2.58 millionDividend Yield0.12%Net Expense Ratio0.78%Aggregate RatingN/A ETF Overview The Strategic CRISPR & Gene Editing Technology ETF (XDNA) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a market-cap-weighted index of companies in developed markets that focus on the advancements in DNA modification technology. XDNA was launched on Jan 12, 2022 and is managed by Kelly. Read More Kelly CRISPR & Gene Editing Technology ETF ExpensesTypeXDNATheme ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.78%0.57%0.57%0.54%0.53%Other Expenses0.00%0.57%0.53%0.38%0.54%Total Expense0.78%0.72%0.75%0.69%0.73%Fee Waiver0.00%-0.72%-0.67%-0.41%-0.68%Net Expense0.78%0.60%0.63%0.61%0.60% Receive XDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kelly CRISPR & Gene Editing Technology ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XDNA ETF News HeadlinesCathie Wood buys the dip in gene-editing firm CRISPR TherapeuticsMarch 11, 2026 | seekingalpha.comCRISPR breakthrough reverses chemotherapy resistance in lung cancerNovember 17, 2025 | msn.comAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly 80% afterward. He also called the housing crisis and the collapse of Bear Stearns and Lehman Brothers before they happened. Now Tilson says the day after this year's midterm elections, America enters a period of economic change unlike anything seen in decades - and most investors are unprepared.September 24 at 1:00 AM | Stansberry Research (Ad)CRISPR Therapeutics Reports Q3 2025 Financial ResultsNovember 12, 2025 | msn.comCHOP, Penn advance CRISPR gene editing with fast-developed treatment for an infant with a rare diseaseMay 15, 2025 | msn.comNobel Prize winners convince court to revive CRISPR patent disputeMay 12, 2025 | reuters.comSee More Headlines XDNA ETF - Frequently Asked Questions How have XDNA shares performed this year? Kelly CRISPR & Gene Editing Technology ETF's stock was trading at $7.38 on January 1st, 2026. Since then, XDNA shares have increased by 0.0% and is now trading at $7.38. How do I buy shares of Kelly CRISPR & Gene Editing Technology ETF? Shares of XDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kelly CRISPR & Gene Editing Technology ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kelly CRISPR & Gene Editing Technology ETF investors own include Meta Platforms (META), RTX (RTX), Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Cloudflare (NET), Birkenstock (BIRK) and Baidu (BIDU). Fund Details IssuerKelly Strategic Management Fund NameKelly CRISPR & Gene Editing Technology ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:XDNA Inception Date1/12/2022 Fund ManagerDustin Lewellyn, Ernesto Tong, Anand Desai WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkStrategic CRISPR & Gene Editing Technology Index CategoryStrategy FocusTheme Development LevelDeveloped Markets RegionGlobal Number of Holdings2 Fund Statistics Assets Under Management$2.58 million Average Daily Volume$0.00 Discount/Premium0.00% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorKelly Strategic Management, LLC CustodianU.S. Bank, N.A. DistributorForeside Fund Services, LLC Transfer AgentU.S. Bancorp Fund Services, LLC TrusteeN/A Lead Market MakerJane Street Miscellaneous Outstanding Shares300,000Beta0.92 Creation Unit25,000 Creation Fee$250.00 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report Top 3 XDNA HoldingsFirst American Government Obligations FundHolding Weight: 49.96%First American Treasury Obligations FundHolding Weight: 49.96%DEPOSITS WITH BROKER FOR SHORT POSITIONSHolding Weight: 0.09%Full Holdings Details This page (NASDAQ:XDNA) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredOn October 7th, your “safest” assets are at riskJeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...Brownstone Research | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kelly CRISPR & Gene Editing Technology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Kelly CRISPR & Gene Editing Technology ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XDNA Stock Alerts